IP Library Granted Patent US 7,105,495
Granted Patent B2
US 7,105,495 · App. 10/406,015 · Granted Sep 12, 2006

Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,105,495
App. No.
10/406,015
Granted
Sep 12, 2006
Kind
B2
Abstract

The invention provides methods for modulating the immune response caused by CpG dinucleotide-containing compounds. The methods according to the invention enables both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications.

Claims (5)

1. A method for modulating the immunostimulatroy effect of a 5′-CpG-3′ dinucleotide containing compound, wherein C is cytosine and G is guanosine or a substituted guanosine, by introducing an immunomodulatory moiety at a position either 5′ or 3′ to the CpG dinucleotide, wherein the immunomodulatory moiety is selected from the group consisting of abasic nucleoside, 1,3-propanediol linker, nitropyrrole, nitroindole, deoxyuridine, inosine, isoguanosine, 2-aminopurine, nebularine, 7-deazaguanosine. 4-thiodeoxyuridine, 4-thiothymidine, d-isoguanosine, d-iso-5-methylcytosine, P-base, and 3′—3′ linkage, and wherein the compound is 12 to 35 nucleotides in length and wherein the compound does not have antisense activity.

2. The method according to claim 1 , wherein the compound has the structure

5′-Yn . . . Y6-Y5-Y4-Y3-Y2-Y1-CG-X1-X2-X3-X4-X5-X6-X7-X8-X9 . . . Xm-3′,

wherein C is cytosine, G is guanosine, or a substituted guanosine, and each X and Y is independently a nucleoside or an immunomodulatory moiety, and n is a number from −6 to +20, and m is a number from −9 to +20.

3. The method according to claim 2 , wherein G is inosine or 7-deazaguanosine.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Nov 30, 2005
From: HYBRIDON, INC
To: IDERA PHARMACEUTICALS, INC
Reel/Frame 017240/0865 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2003
From: AGRAWAL, SUDHIR; KANDIMALLA, EKAMBAR R.
To: HYBRIDON, INC.
Reel/Frame 014433/0801 →